Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

OptimizeRx (OPRX) Shares Outstanding (Weighted Average) (2016 - 2026)

OptimizeRx's Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $18.6 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.43% to $18.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.6 million, a 1.43% increase, with the full-year FY2025 number at $18.6 million, up 1.43% from a year prior.
  • Shares Outstanding (Weighted Average) hit $18.6 million in Q4 2025 for OptimizeRx, roughly flat from $18.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for OPRX hit a ceiling of $18.6 million in Q4 2025 and a floor of $16.1 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $17.7 million across 5 years, with a median of $17.9 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 18.5% in 2021 and later decreased 6.04% in 2023.
  • Tracing OPRX's Shares Outstanding (Weighted Average) over 5 years: stood at $17.2 million in 2021, then grew by 3.23% to $17.8 million in 2022, then dropped by 3.71% to $17.1 million in 2023, then increased by 6.82% to $18.3 million in 2024, then grew by 1.43% to $18.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for OPRX at $18.6 million in Q4 2025, $18.5 million in Q3 2025, and $18.5 million in Q2 2025.